Company intelligence / Profile preview

Vac4All

Ownership: Private
Development stage: Phase 2

Overview

The company's PfPEBS malaria vaccine candidate reached Phase I/II clinical trials but was discontinued in February 2019. The vaccine was being developed for the prevention of falciparum malaria.

Therapeutic areas: Infectious Diseases
Modalities: VaccinesBiofusion conjugate technology
Industry: Biotech

Drug pipeline

8 assets

MSP3-CRM-Vac4All

7 more assets in the full pipeline.

Request access →

Partnerships

Sanofi

Beyond the preview

Go deeper on Vac4All.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vac4All.

Explore the full profile